Novozymes has won a 1.5-year-long case against Danisco concerning infringement of a Novozymes patent on enzymes for bioethanol.
Danisco announced today that the company has withdrawn the infringing product—Spezyme Ethyl—from the market. Spezyme Ethyl is a high-performance thermostable alpha-amylase enzyme for the liquefaction of starch at high temperatures.
In Fall 2004, Novozymes determined that Genencor (later bought by Danisco) was selling enzymes protected by Novozymes’ patent rights to the booming American ethanol market. On 15 March 2005—the same day Novozymes’ patent was issued—Novozymes filed suit for patent infringement in the US District Court for the district of Delaware.
The size of the damages will be decided in the fall. Novozymes has claimed several million US dollars in damages for loss of profits.
We are ready to deliver products (e.g. Liquozyme and Termamyl) to the customers replacing the infringing product that Danisco has withdrawn from the market. We are looking forward to a larger turnover and we have new products in the pipeline for the biofuel market.—Poul Ruben Andersen, Novozymes marketing director for fuel ethanol